Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-17T00:18:26.284Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical data in early intervention

Published online by Cambridge University Press:  12 July 2012

Siegfried Kasper
Siegfried Kasper*
Affiliation:
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
*
Correspondence should be addressed to: Siegfried Kasper, Professor and Chairman, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel 18–20, A – 1090 Vienna, Austria. Phone: +43 1 40400-3568; Fax: +43 1 40400-3099. Email: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Research into early intervention for Alzheimer's disease (AD) and dementia has involved cohort data from large epidemiological studies and data from specifically designed intervention trials. Cohort data indicate that use of nootropics and Ginkgo biloba extract may be associated with a reduced incidence of dementia and death. Data from large trials have often been inconclusive due to issues with poor medication adherence. However, such trials do indicate potential benefits with Gingko biloba extract in terms of reduced incidence of dementia of the AD type, vascular dementia and mixed pathology, reduced progression in terms of the clinical dementia rating and improvements in attention and memory. Furthermore, Gingko biloba extract EGb 761® is a useful option for long-term intervention on the basis of decades of previous experience and an excellent safety record. However, benefits can be expected only with sufficient medication adherence and treatment duration, so clear evidence of a disease-modifying benefit of this extract is needed from adequately designed trials using modern methods to ensure high levels of adherence.

Keywords

adherenceAlzheimer's diseaseattentionclinical studiescohort studiesdementiaepidemiological studiesmemorysafety
Type
Research Article
Information
International Psychogeriatrics , Volume 24 , Supplement S1: The aging brain: current concepts, intervention strategies and the role of Ginkgo biloba extract EGb 761 , August 2012 , pp. S41 - S45
Copyright
Copyright © International Psychogeriatric Association 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andrieu, S. et al. (2003). Association of Alzheimer's disease onset with Ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. Journals of Gerontology, 58, 372–377.Google Scholar
Andrieu, S., Ousset, P. J., Coley, N., Ouzid, M., Mathiex-Fortunet, H. and Vellas, B. (2008). GuidAge study: a 5-year double blind, randomised trial of EGb 761 for the prevention of Alzheimer's disease in elderly subjects with memory complaints. I. Rationale, design and baseline data. Current Alzheimer Research, 5, 406–415.CrossRefGoogle ScholarPubMed
Dartigues, J. F., Carcaillon, L., Helmer, C., Lechevallier, N., Lafuma, A. and Khoshnood, B. (2007). Vasodilators and nootropics as predictors of dementia and mortality in the PAQUID cohort. Journal of the American Geriatrics Society, 55, 395–399.CrossRefGoogle ScholarPubMed
DeKosky, S. T. et al. (2008). Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA, 300, 2253–2262.CrossRefGoogle ScholarPubMed
Dodge, H. H., Zitzelberger, T., Oken, B. S., Howieson, D. and Kaye, J. (2008). A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology, 70, 1809–1817.CrossRefGoogle ScholarPubMed
Grass-Kapanke, B., Busmane, A., Lasmanis, A., Hoerr, R. and Kaschel, R. (2011). Effects of Ginkgo biloba special extract EGb 761® in very mild cognitive impairment (vMCI). Neuroscience & Medicine, 2, 48–56.CrossRefGoogle Scholar
Hampel, H. et al. (2011). Biomarkers for Alzheimer's disease therapeutic trials. Progress in Neurobiology, 95, 579–593CrossRefGoogle ScholarPubMed
Ihl, R., Frölich, L., Winblad, B., Schneider, L., Burns, A. and Möller, H. J.on behalf of the WFSBP Task Force on Treatment Guidelines for Alzheimer's Disease and other dementias (2011). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias. World Journal of Biological Psychiatry, 12, 2–32.CrossRefGoogle ScholarPubMed
Jack, C. R. Jr. et al. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology, 9, 119–128.CrossRefGoogle ScholarPubMed
Jerant, A., Chapman, B., Duberstein, P., Robbins, J. and Franks, P. (2011). Personality and medication non-adherence among older adults enrolled in a six-year trial. British Journal of Health Psychology, 16, 151–169.CrossRefGoogle Scholar
Kaschel, R. (2009). Ginkgo biloba: specificity of neuropsychological improvement–a selective review in search of differential effects. Human Psychopharmacology, 24, 345–370.CrossRefGoogle ScholarPubMed
Kasper, S. and Schubert, H. (2009). Ginkgo-Spezialextrakt EGb 761® in der Behandlung der Demenz: Evidenz für Wirksamkeit und Verträglichkeit. Fortschritte der Neurologie – Psychiatrie, 77, 1–12.CrossRefGoogle Scholar
Snitz, B. E. et al. (2009). Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA, 302, 2663–2670.CrossRefGoogle ScholarPubMed
Vellas, B. et al. for the GuidAge Study Group (2010). Results of GuidAge: a 5-year placebo-controlled study on the efficacy of EGb 761 120 mg to prevent or delay Alzheimer's dementia onset in elderly subjects with memory complaint. Journal of Nutrition, Health & Aging, 14 (Suppl. 2), S23.Google Scholar
Vellas, B. et al. (2011). Prevention trials in Alzheimer's disease: an EU-US Task Force report. Progress in Neurobiology, 95, 594–600.CrossRefGoogle ScholarPubMed